. 2016 Jul 23;3(3):ofw156. doi: 10.1093/ofid/ofw156

Table 3.

Association Between LSM, FIB-4, APRI, Predictive Models, and Mortality

Variable	HR (95% CI)	P Value	aHR (95% CI)^a	P Value
LSM (kPa)
<8.5	Referent		Referent
8.5–12.2	1.25 (.43–3.59)	.6828	1.78 (.60–5.16)	.3064
≥12.3	4.55 (2.21–9.34)	<.0001	5.11 (2.33–11.18)	<.0001
FIB-4
<1.45	Referent		Referent
1.45–3.25	2.01 (.81–4.99)	.1313	2.71 (1.04–7.08)	.0424
>3.25	3.90 (1.63–9.34)	.0023	3.45 (1.43–8.32)	.0059
APRI
<0.5	Referent		Referent
0.5–1.5	1.28 (.53–3.09)	.5812	1.66 (.66–4.19)	.2823
>1.5	2.55 (1.11–5.88)	.0279	2.67 (1.15–6.21)	.0230
FIB-4 best subset model^b
Predicted no/mild stiffness	Referent		Referent
Predicted at least significant stiffness	3.01 (1.55–5.87)	.0012	2.68 (1.36–5.29)	.0044
FIB-4 best subset model^c
Predicted no/mild/significant stiffness	Referent		Referent
Predicted severe stiffness/cirrhosis	3.88 (2.06–7.32)	<.0001	3.20 (1.67–6.14)	.0005
Modified FIB-4 score model^d
<60	Referent		Referent
60–87	1.59 (.63–4.04)	.3296	2.03 (.78–5.43)	.1584
≥88	2.28 (1.11–4.67)	.0242	2.07 (1.00–4.25)	.0487

Abbreviations: aHR, adjusted hazard ratio; APRI, APRI, aminotransferase to platelet ratio index; BMI, body mass index; CI, confidence interval; FIB-4, fibrosis 4; GGT, γ-glutamyl transpeptidase; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment insulin resistance; HR, hazard ratio; LSM, liver stiffness measure.

^a The aHR in each row represents a distinct model that adjusted for alcohol use, BMI, and CD4 count.

^b Predicted to have at least significant liver stiffness at baseline (≥8.5 kPa) based on optimal cutoff using model with FIB-4, GGT, BMI, and HDL.

^c Predicted to have at least severe liver stiffness at baseline (≥12.3 kPa) based on optimal cutoff using model with FIB-4, GGT, HOMA-IR, and HDL.

^d Score calculated as FIB-4 × BMI × log₁₀(GGT), where FIB-4 is 1 = low range (<1.45), 2 = medium range (1.45–3.25), 3 = high range (>3.25).